Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241Phase 4Recruiting
- Sponsor
- Moderna Inc
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Primary endpoints: Geometric Mean Value of Neutralizing Antibody Against COVID-19 Variants at Day 29, Geometric Mean Fold Rise of Neutralizing Antibody Against COVID-19 Variants at Day 29 and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06585241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585241.